Business
IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"
POTOMAC, MD / ACCESS Newswire / October 22, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / October 22, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced that its project "AHA: Agentic Harmonization Assistant" has been selected as a semi-finalist in the prestigious $1 million Alzheimer's Insights AI Prize, Accelerating Discovery with Agentic Intelligence, a competition organized by the Alzheimer's Disease Data Initiative ("ADDI").","length":598,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/afa8c7d1b36ad14bb2f4b970ae21d321"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7BFsLItCJdoua.d4IEpIWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/afa8c7d1b36ad14bb2f4b970ae21d321","width":960,"height":568},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/j.SoAXH8k3_AZvAKZQqmMg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIwO2NmPXdlYnA-/https://media.zenfs.com/en/accesswire.ca/afa8c7d1b36ad14bb2f4b970ae21d321","width":1200,"height":710}},"href":"https://app.accessnewswire.com/imagelibrary/5a9ce6b0-6659-4206-ae4a-ae668f8b0b58/igc-pharma-inc-2025.png","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The ADDI announcement is at this link: ADDI announces semi-finalists.","length":69,"tagName":"p"},{"type":"text","content":""I see this prestigious global recognition as a powerful market signal confirming our leadership in AI-driven Alzheimer's research. This achievement not only validates our proprietary technology but also underscores the caliber of the team driving our AI execution strategy against a field of global leaders".","length":323,"tagName":"p"},{"type":"text","content":""Crucially, this success is a direct outgrowth of our foundational work with MINT-AD, our proprietary deep-learning platform that integrates clinical, neuroimaging, genetics, lifestyle, cognitive, and genomic information. Because of MINT-AD, our proposed AHA platform is not theoretical; it's a rapid expansion of a vali...